CRIS Current Research Information System

PISCAGLIA, FABIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 21.339
AS - Asia 17.345
EU - Europa 14.712
SA - Sud America 1.345
AF - Africa 1.171
OC - Oceania 39
Continente sconosciuto - Info sul continente non disponibili 10
Totale 55.961
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 21.140
SG - Singapore 5.635
CN - Cina 4.827
GB - Regno Unito 3.300
VN - Vietnam 3.271
IT - Italia 2.828
DE - Germania 2.025
SE - Svezia 1.601
HK - Hong Kong 1.408
BR - Brasile 982
IN - India 898
RU - Federazione Russa 855
NL - Olanda 709
FR - Francia 618
IE - Irlanda 616
UA - Ucraina 597
KR - Corea 480
FI - Finlandia 339
ZA - Sudafrica 312
TG - Togo 305
CH - Svizzera 252
CI - Costa d'Avorio 247
EE - Estonia 237
JP - Giappone 211
BG - Bulgaria 171
AR - Argentina 165
SC - Seychelles 132
JO - Giordania 126
AT - Austria 107
CA - Canada 106
ID - Indonesia 106
BE - Belgio 95
NG - Nigeria 81
HR - Croazia 80
MX - Messico 69
EC - Ecuador 68
PL - Polonia 65
ES - Italia 60
PK - Pakistan 54
BD - Bangladesh 47
IR - Iran 39
CL - Cile 36
TR - Turchia 35
GR - Grecia 32
AU - Australia 30
EG - Egitto 27
IQ - Iraq 27
PY - Paraguay 27
TW - Taiwan 25
PE - Perù 24
CZ - Repubblica Ceca 23
CO - Colombia 22
LT - Lituania 22
UZ - Uzbekistan 21
IL - Israele 18
MA - Marocco 17
MY - Malesia 17
LB - Libano 15
RO - Romania 14
AE - Emirati Arabi Uniti 13
PH - Filippine 13
DZ - Algeria 11
PT - Portogallo 11
KE - Kenya 10
UY - Uruguay 9
EU - Europa 8
RS - Serbia 8
SA - Arabia Saudita 8
DK - Danimarca 7
TN - Tunisia 7
AL - Albania 6
AZ - Azerbaigian 6
BA - Bosnia-Erzegovina 6
CR - Costa Rica 6
DO - Repubblica Dominicana 6
NO - Norvegia 6
NZ - Nuova Zelanda 6
VE - Venezuela 6
BO - Bolivia 5
ET - Etiopia 5
KG - Kirghizistan 5
KZ - Kazakistan 5
LV - Lettonia 4
MM - Myanmar 4
TH - Thailandia 4
BH - Bahrain 3
BN - Brunei Darussalam 3
BY - Bielorussia 3
GE - Georgia 3
HU - Ungheria 3
LK - Sri Lanka 3
MD - Moldavia 3
MK - Macedonia 3
MU - Mauritius 3
NP - Nepal 3
PA - Panama 3
PS - Palestinian Territory 3
SK - Slovacchia (Repubblica Slovacca) 3
SN - Senegal 3
AM - Armenia 2
Totale 55.925
Salva come PNG Salva come JPEG
Città #
Singapore 3.706
Southend 2.893
Fairfield 2.464
Ashburn 2.439
Chandler 1.682
Hong Kong 1.387
Dong Ket 1.102
Hefei 1.064
Woodbridge 1.059
Seattle 1.011
Houston 981
Wilmington 951
Santa Clara 938
Cambridge 787
Princeton 754
Beijing 625
Ann Arbor 624
Ho Chi Minh City 619
Dublin 615
Bologna 606
Boardman 569
Seoul 467
Hanoi 463
Jacksonville 364
Lomé 305
Westminster 298
Nanjing 292
Dallas 280
Los Angeles 278
Padova 252
New York 249
Abidjan 247
Helsinki 244
Berlin 232
Munich 231
Bern 218
Milan 212
Buffalo 200
Tokyo 186
Sofia 168
Redondo Beach 161
Saint Petersburg 158
Jinan 155
San Diego 130
Shenyang 129
Turin 127
Amman 126
Rome 124
Frankfurt am Main 118
Changsha 100
Medford 100
Nanchang 100
Bengaluru 95
São Paulo 93
Guangzhou 92
Florence 91
Hebei 91
Shanghai 88
Tianjin 88
Brussels 87
Dearborn 87
Amsterdam 83
Haiphong 76
Abeokuta 73
Chicago 71
Mülheim 71
Nuremberg 71
Falkenstein 69
London 65
Des Moines 64
Vienna 64
Redmond 63
Zhengzhou 61
Jakarta 57
Da Nang 56
Phoenix 56
Bremen 55
Olalla 55
Wuhan 51
Lappeenranta 49
Falls Church 47
Jiaxing 47
The Dalles 46
Brooklyn 45
Bühl 44
Ningbo 43
Turku 41
Norwalk 40
Warsaw 40
Hải Dương 39
Mahé 38
Moscow 38
Orem 36
Verona 36
Düsseldorf 35
Hangzhou 35
Lahore 35
Redwood City 34
Rio de Janeiro 34
Toronto 34
Totale 36.399
Salva come PNG Salva come JPEG
Nome #
Molecular Adsorbent Recirculating System (MARS) application in liver failure: Clinical and hemodepurative results in 22 patients 358
EFSUMB Guidelines on Interventional Ultrasound (INVUS), Part VI - Ultrasound-guided vascular interventions 319
Efficacy of radioembolization according to tumor morphology and portal vein thrombosis inintermediate-advanced hepatocellular carcinoma 288
Guidelines and good clinical practice recommendations for Contrast Enhanced Ultrasound (CEUS) in the liver - update 2012: A WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. 276
Clinical trial: peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation 264
Differences in liver stiffness values obtained with new ultrasound elastography machines and Fibroscan: A comparative study 251
Accuracy of VirtualTouch Acoustic Radiation Force Impulse (ARFI) imaging for the diagnosis of cirrhosis during liver ultrasonography 240
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial 238
A phase I study of continuous hepatic arterial infusion of Irinotecan in patients with locally advanced hepatocellular carcinoma. 236
Laser ablation is superior to TACE in large-sized hepatocellular carcinoma: A pilot case-control study 236
A new priority policy for patients with hepatocellular carcinoma awaiting liver transplantation within the model for end-stage liver disease system. 235
Acute systemic, splanchnic and renal haemodynamic changes induced by molecular adsorbent recirculating system (MARS) treatment in patients with end-stage cirrhosis. 233
Ablation for hepatocellular carcinoma: beyond the standard indications 233
Focal nodular hyperplasia: New findings at Doppler ultrasonography 226
Clinical Impact and Safety of Anticoagulants for Portal Vein Thrombosis in Cirrhosis 223
Adherence to AASLD guidelines for the treatment of hepatocellular carcinoma in clinical practice: experience of the Bologna Liver Oncology Group. 218
Imaging-based diagnosis of benign lesions and pseudolesions in the cirrhotic liver 218
Accuracy of spleen stiffness measurement for the diagnosis of clinically significant portal hypertension in patients with compensated advanced chronic liver disease: a systematic review and individual patient data meta-analysis 214
Evaluation of the impact of transient interruption of antiangiogenic treatment using ultrasound-based techniques in a murine model of hepatocellular carcinoma 213
Ablazione percutanea ecoguidata mediante radiofrequenza di piccoli noduli di HCC: fattori correlati all'esito clinico e alla recidiva di malattia 210
Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: key role of immunosuppression. 208
Use of perfusional angiosonography in liver transplantation and conservative management of post-transplant intra-hepatic pseudo-aneurysm. 207
A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma 204
Usefulness of contrast-enhanced perfusional sonography in the assessment of hepatocellular carcinoma hypervascular at spiral computed tomography. 198
Aflatoxin B1 DNA-Adducts in Hepatocellular Carcinoma from a Low Exposure Area 197
Recalibrating survival prediction among patients receiving trans‐arterial chemoembolization for hepatocellular carcinoma 194
Application of the Intermediate-Stage Subclassification to Patients with Untreated Hepatocellular Carcinoma 192
MiR-494 induces metabolic changes through G6pc targeting and modulates sorafenib response in hepatocellular carcinoma 191
Analysis of risk factors for early hepatic artery thrombosis after liver transplantation. Possible contribution of reperfusion in the early morning. 190
Average treatment effect of hepatic resection versus locoregional therapies for hepatocellular carcinoma 190
Monofocal hepatocellular carcinoma: How much does size matter? 189
An explorative data-analysis to support the choice between hepatic resection and radiofrequency ablation in the treatment of hepatocellular carcinoma. 187
Artificial neural network is superior to MELD in predicting mortality of patients with end-stage liver disease. 186
Nozioni di ecografia Doppler e color-Doppler 186
Validation of noninvasive methods for the assessment of liver fibrosis in patients with recurrent hepatitis C after transplantation. 184
Comparison of International Guidelines for Noninvasive Diagnosis of Hepatocellular Carcinoma 184
Reliability of imaging techniques in assessing portal venous thrombosis in patients with hepatocellular carcinoma candidates for liver transplantation 184
Use of VEGFR-2 Targeted Ultrasound Contrast Agent for the Early Evaluation of Response to Sorafenib in a Mouse Model of Hepatocellular Carcinoma. 184
Characterization of primary and recurrent nodules in liver cirrhosis using contrast-enhanced ultrasound: which vascular criteria should be adopted? 183
Affidabilità della combinazione di angioecografia perfusionale ed altre tecniche di imaging nella valutazione della trombosi portale in pazienti con epatocarcinoma (HCC) candidati al trapianto di fegato 183
Comparison between alcohol- and hepatitis C virus-related hepatocellular carcinoma: clinical presentation, treatments and outcome. 182
The duration of the conventional chemoembolization for hepatocellular carcinoma: factors affecting the procedural time 181
Surveillance for Hepatocellular Carcinoma Also Improves Survival of Incidentally Detected Intrahepatic Cholangiocarcinoma Arisen in Liver Cirrhosis 181
Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma. 180
MiR-30e-3p influences tumor phenotype through MDM2/TP53 axis and predicts sorafenib resistance in hepatocellular carcinoma 180
Assessment of donor steatosis in liver transplantation: is it possible without liver biopsy? 178
EFSUMB Guidelines and Recommendations on the Clinical Use of Ultrasound Elastography.Part 2: Clinical Applications. 178
Quantification of enhancement of focal liver lesions during contrast-enhanced ultrasound (CEUS). Analysis of ten selected frames is more simple but as reliable as the analysis of the entire loop for most parameters. 177
The EFSUMB guidelines and recommendations for the clinical practice of contrast-enhanced ultrasound (CEUS) in Non-Hepatic Applications: Update 2017 (Long Version) 177
Criteria for diagnosing benign portal vein thrombosis in the assessment of patients with cirrhosis and hepatocellular carcinoma for liver transplantation. 177
Development and Validation of a New Prognostic System for Patients with Hepatocellular Carcinoma 176
Characterization of focal liver lesions with contrast-enhanced ultrasound. 175
Assessment of liver fibrosis in trnsplant recipients with recurrent HCV infection: Usefulness of transient elastography. 175
Correlation between LDH levels and response to sorafenib in HCC patients: an analysis of the ITA.LI.CA. database 174
Choledochoscope-assisted percutaneous fibrin glue sealing of bile leak complicating transarterial chemoembolization of hepatocellular carcinoma after liver transplantation. 173
Long term follow-up and outcome of liver transplantation for alcoholic liver disease: a single center case-control study 172
Hepatic artery thrombosis and graft ischemia in presence of preserved arterial inflow: not a contradiction but a real possibilty 171
Extracorporeal Detoxification for Hepatic Failure Using Molecular Adsorbent Recirculating System: Depurative Efficiency and Clinical Results in a Long-Term Follow-Up 171
Impiego clinico del “Fegato Artificiale” MARS: effetti sulle citochine e sui fattori di crescita 170
Diagnostic features of real-time contrast-enhanced ultrasound in focal nodular hyperplasia of the liver. 170
Acoustic Radiation Force Impulse elastography for fibrosis evaluation in patients with chronic hepatitis C: an international multicenter study. 169
Contrast-enhanced ultrasonography to diagnose complicated acute cholecystitis 169
Clinical Impact and behaviour of serum autoantibodies in adult liver transplantation 169
Bidimensional shear wave ultrasound elastography with supersonic imaging to predict presence of oesophageal varices in cirrhosis 169
American College of Radiology Contrast Enhanced Ultrasound Liver Imaging Reporting and Data System (CEUS LI-RADS) for the diagnosis of Hepatocellular Carcinoma: A pictorial essay 168
Inter-operator variability and source of errors in tumour response assessment for hepatocellular carcinoma treated with sorafenib 168
Cost analysis of recall strategies for non-invasive diagnosis of small hepatocellular carcinoma. 168
Landscape of alcohol-related hepatocellular carcinoma in the last 15 years highlights the need to expand surveillance programs 167
Conditional survival after hepatic resection for hepatocellular carcinoma in cirrhotic patients. 167
Stadiazione epatica dei carcinomi gastrointestinali di prima diagnosi mediante angioecografia perfusionale. Confronto con TC spirale ed ecografia convenzionale. 166
A benign tumour of the liver mimicking malignant liver disease--cholangiocellular adenoma. 166
Clinical application of artificial liver support with the Molecular Adsorbent Recirculating System (MARS): impact on cytokines and growth factors 166
Beneficial prognostic effects of aspirin in patients receiving sorafenib for hepatocellular carcinoma: A tale of multiple confounders 166
Real time contrast enhanced ultrasonography in detection of liver metastases from gastrointestinal cancer 165
Comparison of recurrence of hepatocellular carcinoma after resection in patients with cirrhosis to its occurrence in a surveilled cirrhotic population. 165
Characterization of small nodules in cirrhosis by assessment of vascularity: the problem of hypovascular hepatocellular carcinoma. 165
Cholangiocarcinoma in Cirrhosis: Value of Hepatocyte Specific Magnetic Resonance Imaging 165
null 164
Assessment of long-term prognosis at detection of early hepatocellular carcinoma remains unsolved 163
Contrast-enhanced ultrasound in the diagnosis of hepatocellular carcinoma. 163
Metabolic disorders across hepatocellular carcinoma in Italy 163
Thorough assessment of portal venous thrombosis in patients with HCC allows adequate selection of candidates for liver transplantation 163
Field practice studies on sorafenib: lessons in systemic treatment of hepatocellular carcinoma. 162
Impact of gadoxetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance on the non-invasive diagnosis of small hepatocellular carcinoma: a prospective study 161
A relative deficiency of lysosomal acid lypase activity characterizes non-alcoholic fatty liver disease 161
CEUS LI-RADS: algorithm, implementation, and key differences from CT/MRI 161
Corrigendum to “Differences in liver stiffness values obtained with new ultrasound elastography machines and fibroscan: A comparative study” [Dig. Liver Dis. 49 (2017) 802–808](S1590865817302463)(10.1016/j.dld.2017.03.001) 161
Early CTLA4 increase in CD45+ blood cells: an emerging biomarker of atezolizumab–bevacizumab resistance and worse survival in advanced hepatocarcinoma 160
Patients with advanced hepatocellular carcinoma need a personalized management: A lesson from clinical practice 160
Contrast enhanced CT-scan to diagnose intrahepatic cholangiocarcinoma in patients with cirrhosis. 160
Point shear wave ultrasound elastography with Esaote compared to real-time 2D shear wave elastography with supersonic imagine for the quantification of liver stiffness 159
Pattern of macrovascular invasion in hepatocellular carcinoma 159
Preoperative prediction of hepatocellular carcinoma tumour grade and micro-vascular invasion by means of artificial neural network: a pilot study. 158
Caution in the use of boldo in herbal laxatives: a case of hepatotoxicity. 158
An uncommon focal liver lesion: Intrahepatic splenosis 158
Clinical and economical impact of 2010 AASLD guidelines for the diagnosis of hepatocellular carcinoma 157
Characterization of Small Nodules (1-3 cm) in Cirrhosis. The role of Perfusional Angiosonography, Spiral Computed Tomography and Double Contrast Magnetic Resonance 157
Role of Real-Time Contrast-Enhanced Ultrasound in the Assessment of Metastatic Portal Vein Thrombosis. 156
Imaging Diagnosis of Hepatocellular Carcinoma: Recent Advances of Contrast-Enhanced Ultrasonography with SonoVue 156
AISF position paper on nonalcoholic fatty liver disease (NAFLD): updates and future directions. 156
Totale 18.782
Salva come PNG Salva come JPEG
Categoria #
all - tutte 164.904
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 164.904
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20213.329 0 0 0 0 0 294 100 267 448 313 237 1.670
2021/20226.672 640 217 369 381 609 383 147 546 260 328 1.720 1.072
2022/20237.586 823 1.071 381 940 488 573 281 423 1.341 210 596 459
2023/20242.385 173 372 150 194 229 442 113 183 122 191 114 102
2024/202510.738 407 1.519 891 766 1.418 522 805 390 257 986 653 2.124
2025/202613.393 2.614 2.456 2.373 2.025 2.666 1.259 0 0 0 0 0 0
Totale 57.124